Myriad Genetics Inc (MYGN) FinancialsMYGNFinancialMyriad Genetics Inc

Myriad Genetics, Inc. (MYGN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Hereditary Cancer, accounting for 59.8% of total sales, equivalent to $114.10M. Other significant revenue streams include Prenatal and Pharmacogenomics. Understanding this composition is critical for investors evaluating how MYGN navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Myriad Genetics, Inc. maintains a gross margin of 66.60%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -20.40%, while the net margin is -22.65%. These profitability ratios, combined with a Return on Equity (ROE) of -32.54%, provide a clear picture of how effectively MYGN converts its operational activities into shareholder value.

In the context of the broader market, MYGN competes directly with industry leaders such as TMCI and TLSI. With a market capitalization of $289.82M, it holds a significant position in the sector. When comparing efficiency, MYGN's gross margin of 66.60% stands against TMCI's 78.47% and TLSI's 86.78%. Such benchmarking helps identify whether Myriad Genetics, Inc. is trading at a premium or discount relative to its financial performance.

Myriad Genetics has shown declining revenue with total revenue of $190.7 million in Q2 2026, down 11% year-over-year. The gross margin has also decreased to 66.60%, reflecting ongoing financial challenges.